GlassScriptPhysician profile
Debra K Levin
NPI 1518959964
$6,584.63
in general payments reported to CMS, 2019-2025
24 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,526 · 2020: $852 · 2021: $971 · 2022: $314 · 2023: $1,138 · 2024: $502 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,802.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,465.05 | 2020-2025 | Wegovy |
| Amgen INC. | $599.26 | 2019-2021 | |
| Abbvie INC. | $507.61 | 2019-2024 | |
| Glaxosmithkline, LLC. | $342.20 | 2021-2023 | Arexvy, Shingrix |
| Coloplast Corp | $199.01 | 2023 | Titan, Altis |
| Lilly USA, LLC | $196.05 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $156.12 | 2019 | |
| Silk Road Medical, INC. | $134.31 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Merck Sharp & Dohme LLC | $123.18 | 2019-2024 | Verquvo, Gardasil, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $122.06 | 2019 | |
| Akcea Therapeutics, INC. | $121.02 | 2019 | |
| Astellas Pharma US INC | $119.47 | 2019 | |
| Tactile Systems Technology INC | $116.11 | 2025 | Nimbl, Flexitouch Plus |
| Supernus Pharmaceuticals, INC. | $113.07 | 2023 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $86.87 | 2019 | |
| Teleflex LLC | $86.59 | 2025 | Barrigel |
| Medtronic, INC. | $77.78 | 2025 | Venaseal |
| Pfizer INC. | $65.55 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $47.90 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $33.39 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $29.85 | 2023 | |
| Eisai INC. | $24.97 | 2020 | |
| Linus Health, INC. | $15.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.